ArticleFrontiers in oncology2026
Establishment of prognostic nomogram in cervical cancer with hepatitis B virus infection: a retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to identify prognostic factors and establish a nomogram for predicting overall survival (OS) in hepatitis B surface antigen-positive (HBsAg-positive) cervical cancer (CC) patients. Methods: A retrospective analysis of 149 HBsAg-positive CC patients treated at Yunnan Cancer Hospital (2015-2017) was performed. Cox regression identified independent prognostic factors for nomogram development. The nomogram's predictive accuracy and discriminative capability were evaluated through Harrell's concordance index (C-index), calibration plots, and decision curve analysis, and its performance was compared to the International Federation of Gynecology and Obstetrics (FIGO) staging system. Internal validation was conducted using the bootstrap resampling method. Results: Multivariate Cox regression analyses identified tumor stage, baseline serum AST levels, antiviral therapy, lymph node status, and treatment modality as independent prognostic factors for patients with HBsAg-positive CC, all of which were incorporated into the nomogram for OS. The Harrell's C-index of nomogram was 0.817 (95% confidence interval [CI], 0.762-0.873), which was higher than that of FIGO staging system 0.700 (95% CI, 0.637-0.764, Conclusions: This study established a nomogram for the preliminary prognostic evaluation of OS in HBsAg-positive CC patients. Further validation is required prior to its clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.